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Lymph node 8a involvement in pancreatic cancer is associated with
increased tumour burden but not reduced overall survival
Despite improvements in surgical technique and the addition of adjuvant chemotherapy to the management of resectable
pancreatic cancer the outcome remains dismal.Not only will up to a 1/3 of patients who undergo potentially curative surgery
die from recurrent disease within the first 12 months but the actual 5 year survival rate remain as single figure percentages.
Thus, there is much interest in trying to identify preoperatively those patients who are at risk of early death and unlikely
to benefit from an aggressive surgical and oncological approach. Several small studies have suggested that survival in those
patients with involvement of Lymph node (LN) 8a (as defined by the Japanese pancreatic society) or hepatic artery lymph
node is equivalent to having metastatic disease. Hence suggestions to use the intraoperative detection of its involvement as
reason not to proceed with resection.
In this issue of HPB, Philips et al provide what would seem a definitive answer to this question. Over a 10 year period,
420 patients underwent PD of whom 247 had LN8a sampled. The key findings were that it was extremely rare to have
isolated involvement of LN8a (1.2%) in the absence of other nodal involvement, that LN8a positivity was associated with a
higher disease burden but the overall survival for those with and without LN8a involvement was similar. On multivariate
analysis, LN8a involvement was not an independent predictor of survival.
A possible criticism of this study was the potential for selection bias due to significant number of patients being excluded.
In addition, the detail on the nodal assessment was limited to routine H and E staining but no data are given on the number
or thickness of slices taken through each of the LN, and whether this could have resulted in false negatives. Overall, it would
seem unlikely, however, that these factors significantly biased the outcomes when comparing the results to previous studies.
Thus excluding patients for resection on basis of LN8a status would not currently seem justified.
Saxon Connor
Pancreatic fistulae after a pancreatico-duodenectomy: Are
pancreatico-gastrostomies safer that pancreatico-jejunostomies?
What technique is best to re-establish pancreatic-enteric continuity after a pancreaticoduodenectomy (PD)? Yes, we have
heard this question before, and multiple comparisons of pancreatico-jejunostomy (PJ) and pancreatico-gastrostomy (PG)
are available. But, the jury may still be out. Meta-analyses of retrospective studies suggest PG superiority in reducing
pancreatic fistula (PF). Prospective trials comparing both PJ and PG however collectively show no differences in PF,
morbidity, mortality or delayed gastric emptying (DGE). Some argue that inherent bias, trial design flaws, and hetero-
geneous comparisons abound in available evidence, leaving the question open and unanswered. Khalil et al from Montreal
utilize their unique high-volume PD “setup” in a novel “expertise-based” retrospective trial in which outcomes are analyzed
by propensity-score adjustments. At the heart of the analysis is non-purposeful allocation of PD patients to expert surgeons
who in turn perform the technique they prefer most. The goal is to mitigate any confounding element of technical
proficiency/preference. Outcomes for 206 PD patients who underwent PJ (103) or PG (103) are compared for PF, DGE and
total complications. Indeed, this paper may be the first to use the new Comprehensive Complication Index (CCI) since its
introduction in 2013.While admittedly it took me a bit to grasp the value of this study design, the end outcome results were
clear and easy to understand. After propensity-score adjustment for PJ and PG reconstruction options, no significant
differences were found for PF, DGE (grades B/C) or total complications. Does this settle the issue?Who knows? The authors
conclude that pancreatic surgeons should use their preferred best technique to achieve the best outcomes for their patients.
It is hard to argue with that.
Mark Callery
Age is no barrier to tolerability or efficacy of radioembolization for
colorectal liver metastases
Radioembolization is still searching for its precise niche in the armoury of treatments for colorectal liver metastases. The
majority of protocols advise its use in patients who have non-resectable and chemotherapy-resistant liver metastases with
some requiring failure of first line chemotherapy and some second line chemotherapy. Guidance on its use in patients with
extrahepatic sites of disease is also somewhat variable. Economic considerations influence patient selection in a number of
healthcare models in addition to outcome data.
In this edition of HPB,Tohme and colleagues from the University of Pittsburgh explore outcomes of older patients treated
with radioembolization. They have reported outcomes of more than 100 patients older or younger than 70 years treated with
one or more episodes of radioembolization for non-resectable liver metastases which have proved resistant to one or two
chemotherapy regimens. Fatigue is a frequently reported complicating symptom of radioembolization. It might be consid-
ered that elderly patients have less physical reserve. However, the Pittsburgh group found no difference in either frequency
or severity of fatigue in treated patients based on age. Other side effect profiles were also similar suggesting that this
treatment modality is well tolerated by the elderly. In terms of patient survival, again there was no difference in outcome
based on patient age. The major determinant of poor outcome appeared to be the presence of extrahepatic disease but this
was the same irrespective of age.
This article provides evidence that radioembolization is effective and reasonably well tolerated in patients with colorectal
liver metastases and should be considered in motivated patients regardless of age.
Stephen J Wigmore
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